What is Intellia Therapeutics's R&D?

Intellia Therapeutics (NTLA) reported R&D of $80.74M in Q1 2026.

How has Intellia Therapeutics's R&D changed year-over-year?

Intellia Therapeutics's R&D decreased by 25.5% year-over-year, from $108.43M to $80.74M.

What is the long-term trend for Intellia Therapeutics's R&D?

Over 4 years (2021 to 2025), Intellia Therapeutics's R&D has grown at a 14.1% compound annual growth rate (CAGR), from $229.81M to $388.86M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Intellia Therapeutics NTLA R&D

R&D at other companies

Ionis PharmaceuticalsIONS

$228.9M+1.6%

ALN

Alnylam PharmaceuticalsALNY

$364.87M+37.6%

CRISPR TherapeuticsCRSP

$68.57M-5.4%

Beam TherapeuticsBEAM

$104.52M+5.8%

Iovance Biotherapeutics, Inc.IOVA

$62.49M-17.7%

Viridian Therapeutics, Inc.VRDN

$77.63M+1.0%

Other financials

Income statement

See full

Revenue$15.0M-9.5%

Operating income-$100.5M+16.8%

Net income-$96.2M+15.8%

EPS (diluted)-$0.81+26.4%

Balance sheet

See full

Cash & equivalents$134.7M+6.2%

Total debt$80.5M-32.5%

Total equity$620.9M-20.4%

Total assets$758.8M-23.1%

Cash flow

See full

Operating cash flow-$117.3M+21.2%

CapEx$79.0K-89.3%

Free cash flow-$117.4M+21.5%

Valuation

See full

Market cap$2.17B+106%

Enterprise value$2.11B+100%

P/S32.8×+9.7×

Profitability

See full

Operating margin-636.6%-202pp

Net margin-597%-194pp

FCF margin-550.2%-140pp

Returns & leverage

See full

Return on equity-56.3%-1.5pp

Debt / equity0.1×0.0×

Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Intellia Therapeutics's R&D?: Intellia Therapeutics (NTLA) reported R&D of $80.74M in Q1 2026.
How has Intellia Therapeutics's R&D changed year-over-year?: Intellia Therapeutics's R&D decreased by 25.5% year-over-year, from $108.43M to $80.74M.
What is the long-term trend for Intellia Therapeutics's R&D?: Over 4 years (2021 to 2025), Intellia Therapeutics's R&D has grown at a 14.1% compound annual growth rate (CAGR), from $229.81M to $388.86M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.